Medical device maker BD is adding USA capacity for syringes, needles and IV catheters, Plastics Today reported on January 16, 2025.
The investment
- BD spent more than $10 million in 2024 on new needle and syringe lines at its plants in Columbus, Nebraska and Canaan, Connecticut.
- The lines will raise domestic output of safety-engineered injection devices by more than 40% and conventional syringes by more than 50%, adding hundreds of millions of units a year.
- BD hired more than 215 full-time workers at the two sites.
- It plans to invest more than $30 million in 2025 on IV line capacity at its Utah plant.
- The Nebraska and Connecticut plants are the only large-scale syringe plants left in the USA, the report said.
“Domestic manufacturing is crucial for ensuring a resilient supply of essential healthcare devices.”
Eric Borin, BD
Why it matters for Made in USA
Most syringes used in the USA are imported, and the FDA warned about some Chinese-made syringes in 2024. More USA capacity makes the supply less fragile.
FAQ
Where are the plants?
Columbus, Nebraska and Canaan, Connecticut, with IV work in Utah.
How much will output grow?
Conventional syringes by more than 50%, safety devices by more than 40%.
How many jobs?
More than 215 full-time hires.
Source & credit
Source: Plastics Today, January 16, 2025: “BD Makes Firm Commitment to Made-in-USA Medtech Manufacturing”, by Norbert Sparrow.